Sherita Hill Golden1, Nina Shah2, Mohammad Naqibuddin3, Jennifer L Payne4, Felicia Hill-Briggs3, Gary S Wand3, Nae-Yuh Wang5, Susan Langan3, Constantine Lyketsos4. 1. Department of Medicine, Johns Hopkins University, Baltimore, MD; Department of Epidemiology, Johns Hopkins University, Baltimore, MD. Electronic address: sahill@jhmi.edu. 2. Department of Epidemiology, Johns Hopkins University, Baltimore, MD. 3. Department of Medicine, Johns Hopkins University, Baltimore, MD. 4. Department of Psychiatry and Behavioral Sciences, Johns Hopkins University, Baltimore, MD. 5. Department of Medicine, Johns Hopkins University, Baltimore, MD; Department of Epidemiology, Johns Hopkins University, Baltimore, MD; Department of Biostatistics, Johns Hopkins University, Baltimore, MD.
Abstract
OBJECTIVE: To estimate the crude prevalence of minor depressive disorder (MinD) in a clinic-based population of adults with type 2 diabetes. METHODS: We screened a clinical sample of 702 adults with type 2 diabetes for depressive symptoms using the Patient Health Questionnaire-2 and performed a structured diagnostic psychiatric interview on 52 screen-positive and a convenience sample of 51 screen-negative individuals. Depressive disorder diagnoses were made using Diagnostic and Statistical Manual of Mental Disorders IV (DSM-IV) Text Revised criteria and categorized as MinD, major depressive disorder (MDD), or no depressive disorder. We estimated prevalence of MinD and MDD and derived 95% CIs. RESULTS: The crude prevalence of current, past, and current or past MinD was 4.3% (95% CI: 0.9-9.2%), 9.6% (95% CI: 3.9-15.9%), and 13.9% (95% CI: 7.7-21.2%), respectively. The crude prevalence of current, past, and current or past MDD was slightly higher-5.0% (95% CI: 1.9-9.4%), 12.0% (95% CI: 6.1-19.5%), and 17.0% (95% CI: 10.1-24.8%), respectively. There was a high prevalence of coexisting anxiety disorders in individuals with MinD (42.2%) and MDD (8.1%). Hemoglobin A1c levels were not significantly different in individuals with MinD or MDD compared to those without a depressive disorder. CONCLUSIONS: MinD is comparably prevalent to MDD in patients with type 2 diabetes; both disorders are associated with concomitant anxiety disorders. MinD is not included in the DSM-5; however, our data support continuing to examine patients with chronic medical conditions for MinD.
OBJECTIVE: To estimate the crude prevalence of minor depressive disorder (MinD) in a clinic-based population of adults with type 2 diabetes. METHODS: We screened a clinical sample of 702 adults with type 2 diabetes for depressive symptoms using the Patient Health Questionnaire-2 and performed a structured diagnostic psychiatric interview on 52 screen-positive and a convenience sample of 51 screen-negative individuals. Depressive disorder diagnoses were made using Diagnostic and Statistical Manual of Mental Disorders IV (DSM-IV) Text Revised criteria and categorized as MinD, major depressive disorder (MDD), or no depressive disorder. We estimated prevalence of MinD and MDD and derived 95% CIs. RESULTS: The crude prevalence of current, past, and current or past MinD was 4.3% (95% CI: 0.9-9.2%), 9.6% (95% CI: 3.9-15.9%), and 13.9% (95% CI: 7.7-21.2%), respectively. The crude prevalence of current, past, and current or past MDD was slightly higher-5.0% (95% CI: 1.9-9.4%), 12.0% (95% CI: 6.1-19.5%), and 17.0% (95% CI: 10.1-24.8%), respectively. There was a high prevalence of coexisting anxiety disorders in individuals with MinD (42.2%) and MDD (8.1%). Hemoglobin A1c levels were not significantly different in individuals with MinD or MDD compared to those without a depressive disorder. CONCLUSIONS: MinD is comparably prevalent to MDD in patients with type 2 diabetes; both disorders are associated with concomitant anxiety disorders. MinD is not included in the DSM-5; however, our data support continuing to examine patients with chronic medical conditions for MinD.
Authors: Wayne Katon; Joan Russo; Elizabeth H B Lin; Susan R Heckbert; Paul Ciechanowski; Evette J Ludman; Michael Von Korff Journal: Psychosomatics Date: 2009 Nov-Dec Impact factor: 2.386
Authors: Ana Claudia C de Ornelas Maia; Arthur de Azevedo Braga; Amanda Brouwers; Antonio Egidio Nardi; Adriana Cardoso de Oliveira e Silva Journal: Compr Psychiatry Date: 2012-04-21 Impact factor: 3.735
Authors: Jay C Fournier; Robert J DeRubeis; Steven D Hollon; Sona Dimidjian; Jay D Amsterdam; Richard C Shelton; Jan Fawcett Journal: JAMA Date: 2010-01-06 Impact factor: 56.272
Authors: Marianne McCollum; Samuel L Ellis; Judith G Regensteiner; Weiming Zhang; Patrick W Sullivan Journal: Am J Manag Care Date: 2007-02 Impact factor: 2.229
Authors: Jennifer K Taylor; Michael Schoenbaum; Wayne J Katon; Harold A Pincus; Diane M Hogan; Jurgen Unutzer Journal: Am J Manag Care Date: 2008-08 Impact factor: 2.229
Authors: Jeffrey S Gonzalez; Steven A Safren; Enrico Cagliero; Deborah J Wexler; Linda Delahanty; Eve Wittenberg; Mark A Blais; James B Meigs; Richard W Grant Journal: Diabetes Care Date: 2007-05-29 Impact factor: 19.112
Authors: Corrado Barbui; Andrea Cipriani; Vikram Patel; José L Ayuso-Mateos; Mark van Ommeren Journal: Br J Psychiatry Date: 2011-01 Impact factor: 9.319
Authors: Na Shin; Felicia Hill-Briggs; Susan Langan; Jennifer L Payne; Constantine Lyketsos; Sherita Hill Golden Journal: J Diabetes Complications Date: 2017-02-12 Impact factor: 2.852
Authors: Mohammed M Alshehri; Aqeel M Alenazi; Jeffrey C Hoover; Shaima A Alothman; Milind A Phadnis; Christie A Befort; John M Miles; Jason L Rucker; Patricia M Kluding; Catherine F Siengsukon Journal: JMIR Res Protoc Date: 2019-12-19